Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 2,671 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Active, not recruiting Phase 2 Interventional

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

NCT04577300
View directory record Official record
Conditions
Glaucoma
Interventions
NT-501, Sham comparator
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 4, 2026, 5:07 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Affixing Polypropylene Mesh Using Barbed Suture (Quill™ Srs) During Laparoscopic Sacrocolpopexy Randomized Controlled Trial (Quill Lsc)

NCT01551992
View directory record Official record
Conditions
Prolapse
Interventions
Quill suture vs. Interrupted suture
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

NCT03616964
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

NCT02440464
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Nov 4, 2026, 5:07 PM EST
Terminated Phase 1 Interventional

A Study of MRx-4DP0004 in Asthma

NCT03851250
View directory record Official record
Conditions
Asthma
Interventions
MRx-4DP0004, Placebo
Drug
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Nov 4, 2026, 5:07 PM EST
Recruiting Not applicable Interventional

Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders

NCT05726591
View directory record Official record
Conditions
Cerebral Palsy, Muscular Dystrophy, Spina Bifida, Incomplete Spinal Cord Injury
Interventions
EA-KAFO
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
3 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer

NCT02716974
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Bicalutamide, Docetaxel, Prostatectomy, Radiation
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional

Internet Intervention for Adolescents With Chronic Pain

NCT01316471
View directory record Official record
Conditions
Chronic Pain, Abdominal Pain, Headache
Interventions
Online Behavioral Intervention, Education: Online Patient Education
Behavioral · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

NCT04570644
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional

Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

NCT00069316
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-IgG-am
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 4, 2026, 5:07 PM EST
Active, not recruiting Phase 2 Interventional

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

NCT05063916
View directory record Official record
Conditions
Carcinomas, Cervix Cancer, Cervical Cancer
Interventions
AK104
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional Results available

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

NCT02701400
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Durvalumab, Hypofractionated Radiation Therapy, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Nov 4, 2026, 5:07 PM EST
Terminated Phase 2 Interventional

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Lucanthone, Temozolomide (TMZ), Radiation, Placebo
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 3 Interventional Results available

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 4, 2026, 5:07 PM EST
Not listed Phase 2 Interventional

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

NCT03813056
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Glanatec, Optive, Ophthalmic Solution, Descemet Membrane Endothelial Keratoplasty
Drug · Procedure
Lead sponsor
Michael D. Straiko, MD
Other
Eligibility
30 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

NCT02330653
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Fecal Microbiota Transplant (FMT), Placebo
Biological
Lead sponsor
Stacy A. Kahn
Other
Eligibility
5 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 4, 2026, 5:07 PM EST
Completed Not applicable Interventional

Transfusion Requirements in Cardiac Surgery

NCT01484639
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Liberal transfusion triggers, Restrictive transfusion triggers
Other
Lead sponsor
Nadine Shehata
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Nov 4, 2026, 5:07 PM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:07 PM EST
Completed Not applicable Interventional

Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer

NCT02096783
View directory record Official record
Conditions
Anxiety Disorder, Cervical Cancer, Endometrial Cancer, Female Reproductive Cancer, Gestational Trophoblastic Tumor, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Sexual Dysfunction, Uterine Sarcoma, Vaginal Cancer, Vulvar Cancer
Interventions
informational intervention, counseling intervention, questionnaire administration
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

NCT01343966
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Nov 4, 2026, 5:07 PM EST
Recruiting Phase 3 Interventional

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
28
States / cities
Fresno, California • Glendale, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 4, 2026, 5:07 PM EST
Completed Phase 2 Interventional

Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288
View directory record Official record
Conditions
Asthma
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Long Beach, California • Mission Viejo, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Nov 4, 2026, 5:07 PM EST
Not yet recruiting Phase 2 Interventional

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

NCT05521997
View directory record Official record
Conditions
Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
Interventions
Telaglenastat, Radiation treatment, Cisplatin
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 4, 2026, 5:07 PM EST